Advanced breast cancer: An evaluation of the cost of recurrence;Cancer du sein au stade avance: Evaluation du cout de la recidive

Bulletin du Cancer

Volumn 86, Issue 6, 1999, Pages 585-590

  Bercez, Caroline ^a   Lebrun, Thérèse ^b   Bonneterre, Marie Édith ^a   Selke, Bernard ^b   Lenne, Xavier ^b   Bonneterre, Jacques ^a  

^a CENTRE OSCAR LAMBRET   (France)

^b Sociologiques et de Gestion   (France)

Author keywords

Breast cancer; Cost; Recurrence

Indexed keywords

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; DRUG COST; FRANCE; HEALTH ECONOMICS; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; METASTASIS;

BREAST NEOPLASMS; COSTS AND COST ANALYSIS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 0032873045     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. 1. Early Breast Cancer Trialist's collaborative group. Systemic treatment of early breast cancer by hormonal cytotoxic or immune-therapy. 133 randomized trials involving 31 000 recurrences and 24 000 death among 75 000 women. Lancet 1992 ; 339 : 1-15, 71-85.
2. 2. Lebrun T, Selke B, Bercez C, Bonneterre ME, Lenne X, Sailly JC, Bonneterre J. Évaluation médico-économique en cancérologie. Bull Cancer 1997 ; 84 : 543-6.
3. 3. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996 ; 14 : 2738-46.
4. 4. Friedlander ML, Tattersall MHN. Counting the costs of cancer therapy. Eur J Cancer Clin Oncol 1982 ; 18 : 1237-41.
5. 5. de Koning HJ, Van Ineveld BM, de Hacs CJM, et al. Advanced breast cancer and its prevention by screening. Br J Cancer 1992 ; 65 : 950-5.
6. 6. Hurley SF, Huggins RM, Snyder RD, et al. The costs of breast cancer recurrences. Br J Cancer 1992 ; 65 : 449-55.
7. 7. Richards MA, Brayshers S, Gregory WM, et al. Advanced breast cancer: use of resources and cost implications. Br J Cancer 1993 ; 67 : 856-60.
8. 8. Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity, and directs costs of colon, prostate and breast cancer care. J Natl Cancer Inst 1995 ; 87 : 417-25.
9. 9. Launois R, Reboul-Marry J, Henry B, Bonneterre J. A cost-utility analysis of second line chemotherapy in metastatic breast cancer. Pharmacoeconomics 1996 ; 10 : 504-21.